摘要
Abstract
Objective To discuss the clinic effect and adverse reaction of low-dose tacrolimus in the treatment of refractory myasthenia gravis(MG).Methods 14 cases of refractory myasthenia gravis patients admitted from 2011 April to 2013 April were selected ,all patients took 0.1 mg · kg-1 · d-1 tacrolimus on the basis of prior treatment ,and took 20 weeks as a course of treatment. The activities of daily living scale (ADL) ,the United States of America MG Foundation (MGFA) evaluation of dis-easeseverityscale,Ossermanratingandhandmusclestrengthtable(MMT)wereusedtoevaluatetheclinicseffectoflow-dose tacrolimus on patients with refractory myasthenia gravis in the fourth week ,8th week ,16th week and 20th week of treatment process ,and the adverse reactions were detected and recorded. Results All patients were treated for 20 weeks. Compared with pretherapy ,each index of patients improved significantly after 20 weeks ,the degree of improvement in ADL was 49.5% ~100% ,the degree of improvement in MGFA was 36.5% ~89.6% ,Osserman rating decreased 2 levels ,the degree of improve-ment in MMT was 55.3% ~90.8% ,compared with pretherapy ,the difference was significant ,with statistical significance (P<0.05). In addition ,only 2 cases among 14 patients had a headache ,dizziness ,high blood pressure and other adverse reac-tions which released within one week ,and there was not any adverse reaction on other patients.Conclusion Long-term low-dose tacrolimus in the treatment of refractory myasthenia gravis was safe and effective ,but because of the small sample size , there still needs further high quality study to verify the clinical effects of the drug.关键词
他克莫司/难治性重症肌无力Key words
Tacrolimus/Refractory myasthenia gravis分类
医药卫生
